Longevity Biotech

Longevity Biotech is a private, pre-revenue biotech firm founded in 2018 and based in San Francisco, operating in the RNA & Gene Therapy sector with a focus on neurodegeneration. The company is advancing a pipeline led by LBT-3627, which is in clinical trials for Parkinson's Disease, powered by its dual-platform approach of immune profiling and synthetic peptide engineering. It has secured non-dilutive funding from prestigious foundations and government agencies, positioning it to address a significant unmet medical need in a challenging therapeutic area. The company's strategy hinges on shifting the treatment paradigm from symptom management to disease modification through immune rebalancing.

Two complementary platforms: 1) Precision Neuroscience Platform™ for immune system profiling, and 2) Hybridtide™ Platform for developing synthetic peptide-based therapeutics designed to rebalance the immune system.

Longevity Biotech operates in the highly competitive and crowded neurodegenerative disease space, competing with large pharma and numerous biotechs exploring amyloid, tau, genetic, and other immune-modulating approaches. Its differentiation lies in its specific combination of immune profiling and synthetic peptide therapy, a niche but unproven strategy.